These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 22332769)

  • 61. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
    Wong MK; Jarkowski A
    Pharmacotherapy; 2009 Apr; 29(4):473-8. PubMed ID: 19323623
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
    Siebels M; Staehler M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
    Aktuelle Urol; 2010 Mar; 41(2):122-30. PubMed ID: 19937556
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
    Hahn OM; Yang C; Medved M; Karczmar G; Kistner E; Karrison T; Manchen E; Mitchell M; Ratain MJ; Stadler WM
    J Clin Oncol; 2008 Oct; 26(28):4572-8. PubMed ID: 18824708
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sorafenib.
    Hasskarl J
    Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis.
    Ferraris E; Di Cesare P; Lasagna A; Paglino C; Imarisio I; Porta C
    Tumori; 2009; 95(4):542-4. PubMed ID: 19856673
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Molecular targeted therapy for renal cell carcinoma and other urological cancers].
    Miyake H; Fujisawa M
    Nihon Rinsho; 2010 Oct; 68(10):1871-5. PubMed ID: 20954332
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.
    Albiges L; Oudard S; Negrier S; Caty A; Gravis G; Joly F; Duclos B; Geoffrois L; Rolland F; Guillot A; Laguerre B; Legouffe E; Kohser F; Dietrich PY; Theodore CA; Escudier B
    J Clin Oncol; 2012 Feb; 30(5):482-7. PubMed ID: 22231040
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Sorafenib TARGET trial results in Spanish patients.
    Bellmunt J; González-Larriba JL; Climent MA; López-Vivanco G; Urruticoechea L; Albanell J
    Clin Transl Oncol; 2007 Oct; 9(10):671-3. PubMed ID: 17974528
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Experience with sorafenib and the elderly patient.
    Dutcher JP; Tannir N; Bellmunt J; Escudier B
    Med Oncol; 2010 Dec; 27(4):1359-70. PubMed ID: 20043216
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.
    Guevremont C; Alasker A; Karakiewicz PI
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):170-9. PubMed ID: 19528803
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Re: Sequential sorafenib and sunitinib for renal cell carcinoma M. P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni and B. Escudier J Urol 2009; 182: 29-34.
    Di Lorenzo G; Autorino R
    J Urol; 2010 Feb; 183(2):824-5; author reply 825. PubMed ID: 20022057
    [No Abstract]   [Full Text] [Related]  

  • 72. Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.
    Strumberg D
    J Clin Oncol; 2008 Jul; 26(20):3469-71; author reply 2471. PubMed ID: 18612169
    [No Abstract]   [Full Text] [Related]  

  • 73. [Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma].
    Ondrácková B; Demlová R; Komínek J
    Klin Onkol; 2010; 23(6):439-45. PubMed ID: 21351422
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].
    Staehler M; Haseke N; Schöppler G; Stadler T; Heinemann G; Stief CG
    Urologe A; 2006 Oct; 45(10):1333-42; quiz 1343. PubMed ID: 17021905
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.
    Yuasa T; Urakami S; Yamamoto S; Yonese J; Nakano K; Kodaira M; Takahashi S; Hatake K; Inamura K; Ishikwa Y; Fukui I
    Urology; 2011 Apr; 77(4):831-5. PubMed ID: 21316083
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.
    Tamaskar I; Bukowski R; Elson P; Ioachimescu AG; Wood L; Dreicer R; Mekhail T; Garcia J; Rini BI
    Ann Oncol; 2008 Feb; 19(2):265-8. PubMed ID: 17962201
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
    Miller K; Bergmann L; Albers P; Jäger E; Jakse G; Geschwend JE; Marschner N
    Aktuelle Urol; 2007 Jul; 38(4):328-30. PubMed ID: 17647172
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation.
    Miyake H; Kurahashi T; Yamanaka K; Kondo Y; Takenaka A; Inoue TA; Fujisawa M
    BJU Int; 2010 Dec; 106(11):1643-7. PubMed ID: 20553261
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
    Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
    Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Major treatment improvements encourage kidney cancer researchers to seek further gains.
    Tuma RS
    J Natl Cancer Inst; 2008 Sep; 100(17):1202-3. PubMed ID: 18728277
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.